136 related articles for article (PubMed ID: 9487957)
1. Targeted radiotherapy for neuroblastoma.
Meller S
Arch Dis Child; 1997 Nov; 77(5):389-91. PubMed ID: 9487957
[No Abstract] [Full Text] [Related]
2. The role of 131I-MIBG in high-risk neuroblastoma treatment.
Lessig MK
J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
[TBL] [Abstract][Full Text] [Related]
3. Letter to the editor.
Kono Y; Shimizu Y; Wakatsuki Y; Yasui N; Aso T; Kawamoto H; Kurihara H
Radiat Prot Dosimetry; 2015 Mar; 163(4):533-4. PubMed ID: 25227441
[No Abstract] [Full Text] [Related]
4. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.
Mastrangelo S; Rufini V; Ruggiero A; Di Giannatale A; Riccardi R
Pediatr Blood Cancer; 2011 Jul; 56(7):1032-40. PubMed ID: 21344615
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.
Takahashi H; Manabe A; Aoyama C; Kamiya T; Kato I; Takusagawa A; Ogawa C; Ozawa M; Hosoya R; Yokoyama K
Pediatr Blood Cancer; 2008 Mar; 50(3):676-8. PubMed ID: 17243128
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma.
Wilson JS; Gains JE; Moroz V; Wheatley K; Gaze MN
Eur J Cancer; 2014 Mar; 50(4):801-15. PubMed ID: 24333097
[TBL] [Abstract][Full Text] [Related]
7. Hypothyroidism after treatment of metastatic neuroblastoma.
Lackner H; Urban C; Sovinz P; Nebl A; Schmidt S; Benesch M; Schwinger W
Pediatr Blood Cancer; 2010 Oct; 55(4):768. PubMed ID: 20806369
[No Abstract] [Full Text] [Related]
8. Neuroblastoma maturation by [(131)I] metaiodobenzylguanidine in chemoresistant neuroblastoma.
Ben Arush MW; Ben Itzhak O; Yossilevski G; El Hasid R; Postovsky S; Israel O
Med Pediatr Oncol; 1999 Oct; 33(4):418-9. PubMed ID: 10491557
[No Abstract] [Full Text] [Related]
9. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
Gaze MN; Gains JE; Walker C; Bomanji JB
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience.
Shusterman S; Grant FD; Lorenzen W; Davis RT; Laffin S; Drubach LA; Fahey FH; Treves ST
Semin Nucl Med; 2011 Sep; 41(5):354-63. PubMed ID: 21803185
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma therapy using radiolabelled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents.
Mairs RJ
Eur J Cancer; 1999 Aug; 35(8):1171-3. PubMed ID: 10615225
[No Abstract] [Full Text] [Related]
12. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE
Br J Radiol; 1995 Nov; 68(815):1263. PubMed ID: 8542240
[No Abstract] [Full Text] [Related]
14. Meta-iodobenzylguanidine in neuroblastoma: from diagnosis to therapy.
Mitjavila M
Nucl Med Commun; 2002 Jan; 23(1):3-4. PubMed ID: 11748431
[No Abstract] [Full Text] [Related]
15. Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Prog Clin Biol Res; 1991; 366():455-61. PubMed ID: 2068160
[No Abstract] [Full Text] [Related]
16. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
17. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voûte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
18. [Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].
Sudbrock F; Eschner W; Schmidt M; Simon T; Hero B; Schicha H
Nuklearmedizin; 2006; 45(6):254-61. PubMed ID: 17149494
[TBL] [Abstract][Full Text] [Related]
19. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy.
Voûte PA; Hoefnagel CA; de Kraker J; Valdes Olmos R; Bakker DJ; van de Kleij AJ
Prog Clin Biol Res; 1991; 366():439-45. PubMed ID: 2068157
[No Abstract] [Full Text] [Related]
20. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
